Sugi Predict

Sugi Predict / Compounds / SCHEMBL2035487

SCHEMBL2035487

SCHEMBL2035487

Cc1ccnc(NC(=O)C(C)(C)C)c1

nearest known ligand 0.68

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.68
▸ NPC1 O15118 11/20 0.54
▸ RAB9A P51151 11/20 0.54
▸ SMN1; SMN2 Q16637 8/20 0.54
▸ TP53 P04637 5/20 0.54
▸ PKM P14618 3/20 0.54
▸ KMT2A Q03164 6/20 0.51
▸ MEN1 O00255 3/20 0.51
▸ ALDH1A1 P00352 2/20 0.51
▸ GBA1 P04062 1/20 0.51
▸ CYP1A2 P05177 1/20 0.51
▸ MAPT P10636 1/20 0.51
▸ CYP2C19 P33261 1/20 0.51
▸ SORT1 Q99523 1/20 0.51
▸ TSHR P16473 1/20 0.51
▸ POLB P06746 1/20 0.50
▸ NFKB1 P19838 1/20 0.50
▸ NFKB2 Q00653 1/20 0.50
▸ RELA Q04206 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25130754 0.85 NPC1 (0.54) LMNANPC1RAB9ASMN1; SMN2TP53
SCHEMBL18785787 0.83 LMNA (0.53) LMNANPC1RAB9ASMN1; SMN2PKM
SCHEMBL829141 0.82 RAB9A (0.62) LMNANPC1RAB9ASMN1; SMN2TP53
SCHEMBL26625247 0.82 NPC1 (0.53) LMNANPC1RAB9ASMN1; SMN2TP53
SCHEMBL14809290 0.81 ABL1 (0.50) LMNANPC1RAB9ASMN1; SMN2TP53
SCHEMBL12516546 0.81 LMNA (0.49) LMNANPC1RAB9ASMN1; SMN2TP53
SCHEMBL25240657 0.81 LMNA (0.49) LMNANPC1RAB9ASMN1; SMN2KMT2A
SCHEMBL209579 0.81 LMNA (0.49) LMNANPC1RAB9AKMT2AMEN1
SCHEMBL31420103 0.81 LMNA (0.49) LMNANPC1RAB9AKMT2AMEN1
SCHEMBL19962825 0.81 LMNA (0.53) LMNANPC1RAB9ASMN1; SMN2TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018002-B2 Certain chemical entities, compositions, and methods NEUPHARMA, INC (US) 2024-06-25 — — US disclosed
US-RE49931-E1 [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-04-23 — — US disclosed
US-RE49880-E1 [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds BRISTOL-MYERS SQUIBB COMPANY (US) 2024-03-26 — — US disclosed
WO-2023218201-A1 IKK INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-11-16 — — WO disclosed
US-20230052017-A1 New compounds for treatment of diseases related to DUX4 expression Facio Intellectual Property B.V. (NL) 2023-02-16 — — US disclosed
US-20230043970-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC 2023-02-09 — — US disclosed
US-11208388-B2 Certain chemical entities, compositions, and methods NEUPHARMA, INC (US) 2021-12-28 — — US disclosed
WO-2021105474-A1 NEW COMPOUNDS FOR TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION Facio Intellectual Property B.V. (NL) 2021-06-03 — — WO disclosed
US-20200172495-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2020-06-04 — — US disclosed
US-20180072688-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS NEUPHARMA, INC. 2018-03-15 — — US disclosed
EP-1836211-A1 MACROLIDES Pfizer Products Incorporated (US) 2007-09-26 — — EP disclosed
WO-2006067589-A1 MACROLIDES PFIZER PRODUCTS INC. (US) 2006-06-29 — — WO disclosed
US-20060135447-A1 Macrolides CHUPAK LOUIS S 2006-06-22 — — US disclosed
EP-0988045-B1 PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS NIELSEN PETER EIGIL (DK) 2006-02-08 — — EP disclosed
US-6632919-B1 Bind Watson-Crick base pairs in a double helix; specific for thymidine Nielsen, Peter (DK) 2003-10-14 — — US disclosed
EP-0988045-A4 PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS NIELSEN PETER EIGIL (DK) 2002-07-24 — — EP disclosed
EP-0988045-A1 PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS NIELSEN, Peter Eigil (DK) 2000-03-29 — — EP disclosed
US-5972975-A Substituted 2-aminopyridines as inhibitors of nitric oxide synthase MERCK & CO., INC. (US) 1999-10-26 — — US disclosed
WO-1998052595-A1 PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS ISIS PHARMACEUTICALS, INC. (US) 1998-11-26 — — WO disclosed
WO-1996018616-A1 SUBSTITUTED 2-AMINOPYRIDINES AS INHIBITORS OF NITRIC OXIDE SYNTHASE MERCK & CO., INC. (US) 1996-06-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230043970-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS BRAF, PIK3CA, PLK1 LMNA 1523/4885NPC1 1884/4885RAB9A 2457/4885
US-12018002-B2 Certain chemical entities, compositions, and methods BRAF, PIK3CA, PLK1 LMNA 1523/4885NPC1 1884/4885RAB9A 2457/4885
US-20060135447-A1 Macrolides LCAT, NOP2, HDAC6 LMNA 660/4885NPC1 16/4885RAB9A 2242/4885
US-11208388-B2 Certain chemical entities, compositions, and methods BRAF, PIK3CA, PLK1 LMNA 1523/4885NPC1 1884/4885RAB9A 2457/4885
US-20180072688-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS BRAF, PIK3CA, PLK1 LMNA 1523/4885NPC1 1884/4885RAB9A 2457/4885
US-20230052017-A1 New compounds for treatment of diseases related to DUX4 expression SMN1; SMN2, UTRN, DDX21 LMNA 919/4885NPC1 2644/4885RAB9A 827/4885
US-20200172495-A1 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS BRAF, PIK3CA, PLK1 LMNA 1523/4885NPC1 1884/4885RAB9A 2457/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.